In vivo Drug Screening Platform
Efficacy Predict Toll for Cancer Research
HOW IT WORKS
Companion animals can be used as a informative model in the preclinical development and discovery of novel cancer treatment.
Studies in dogs provide guidance for conducting similar investigation in human patients.
This model helps to evaluate the efficacy and feasibility of new compounds and can inform the GO/NO-GO decision in clinical drug development
Selected compound with anti-cancer activity demonstrated in vitro and mice studies
We design and conduct
companion animals trials in
our veterinary international
practices network
High predictivity
efficacy results
Go/No-Go Decision
Examples of Preclinical Investigation in Companion Animals
Acalabrutinib
FDA approved for human use
Companion animals trial suggest that acalabrutinib is safe and exhibits activity in canine B-cell lymphoma patients and support the use of canine lymphoma as a relevant model for human non-Hodgkin lymphoma (NHL).
Hydroxychloroquine
Phase II human trial completed
Demonstration of target inhibition in companion animal trial. Studies in dogs were used as a proof of target and refined measure of drug exposure
Ibrutinib
FDA approved for human use
Validation of biomarker test for use in human trials; dose modulation. Companion animals trial demonstrated efficacy and surrogate endpoint.
Ganetespib
Phase III human trials
Proof-of-target for IND application; defined PK/PD relationship. Determined toxicity, biomarkers, and biologic activity
NHS-IL12
Phase I human trials ongoing
PK, PD, efficacy and toxicity studies were conducted in companion animals naturally affected with malignant melanoma
Decision was made to not move forward with human studies based on companion animals trials results.
https://www.ncbi.nlm.nih.gov/books/NBK338437/
Assessed single-agent activity and toxicity for development of tolerable dosing regimen.
Determined dosing regimen and supportive care protocolsin companion animals. Identified adverse events, dose, and regimen.
Phase I study for lymphoma-bearing dogs to evaluate differential efficacy, pharmacodynamics, toxicology, and pharmacokinetics, supporting their further clinical development.
Companion animal trials confirmed inhibition target and tumor response. Masitinib is EMA-approved for veterinary use.